కీమోథెరపీ: ఓపెన్ యాక్సెస్
అందరికి ప్రవేశం

నైరూప్య

SFK Inhibitors as New Strategy for RMS Treatment

Luigi Bagella and Irene Marchesi

A new study investigates about the activity of a new SFK inhibitor in RMS. SI221 is a pyrazolo [3,4-d] pyrimidine derivative able to reduce both apoptosis and differentiation in eRMS and aRMS. SFKs are frequently overexpressed in RMS and their inhibition can be a good strategy for RMS treatment. Rhabdomyosarcoma (RMS) represents approximately half of the total pediatric soft tissue sarcoma (STS), slightly more frequent in males but equally distributed across racial groups [1]. RMS is characterized by the expression of genes involved in the early myogenesis which fail to complete differentiation and cell cycle arrest [2]. It can be divided into 2 major histological subtypes: embryonal (eRMS), mostly found in childhood, and alveolar (aRMS) common in both children and adults [1].